Protein Expression Market to Reach $6.3 Billion by 2035, Growing at 7.8% CAGR | Thermo Fisher Scientific, GenScript Biotech, WuXi Biologics

The global protein expression market, valued at USD 3.0 billion in 2025, will reach USD 3.2 billion in 2026 and climb to USD 6.3 billion by 2035, advancing at a compound annual growth rate of 7.8% across the forecast period. The growth is grounded in concrete commercial activity: close to 20 protein therapeutics received USFDA approval in the last 12 months alone, and 50% of the world's top-selling drugs are already protein-based. For biopharma executives, investors, and research organizations, this market represents one of the most clearly defined growth opportunities in life sciences today.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/protein-expression-market/request-sample.html

MARKET OVERVIEW
Protein expression, the biotechnological process for producing specific proteins for research and commercial use, underpins the development of a large and expanding share of the global drug pipeline. Biopharmaceutical companies rely on these systems to manufacture recombinant proteins at scale, and the pace of adoption is accelerating. More than 6,500 patents related to protein expression have been granted since 2023, a signal that innovation in this field is intensifying, not plateauing.

The commercial logic is straightforward. Protein expression systems offer higher yields, shorter development timelines, and lower production costs compared to legacy approaches. They also allow manufacturers to produce a broad range of target molecules by adjusting system components, an important capability as drug developers shift toward personalized and precision therapies. The US FDA is expected to approve more than 10 novel personalized therapeutic modalities per year on an ongoing basis, a projection that keeps demand for advanced protein production infrastructure at consistently high levels.

Recent industry activity reinforces this trajectory. In March 2025, WuXi Biologics launched EffiX, a proprietary E. coli expression system for producing non-monoclonal antibody recombinant proteins and plasmid DNA. That same month, Ailurus updated its PandaPure Protein System for E. coli applications. In May 2025, Nuclera partnered with Cytiva to integrate its eProtein Discovery System with Cytiva's Biacore SPR technology, targeting faster drug research and biologics development. These are not isolated announcements; they reflect a market where both established players and newer entrants are actively competing to capture share.

KEY GROWTH DRIVERS
Rising Demand for Protein Therapeutics. The pipeline of protein-based drugs treating oncological, cardiovascular, and metabolic disorders continues to expand. Companies are now evaluating oral proteins and peptides as therapeutic formats, extending the clinical reach of protein expression beyond injectable biologics and broadening the addressable market for expression system providers.

Accelerating Personalized Medicine Adoption. Demand for precision therapies is pushing pharmaceutical and biotechnology companies to adopt flexible, high-output protein production capabilities. The expectation that the FDA will approve more than 10 personalized therapeutic modalities annually creates a sustained pull for expression services and technologies across the entire drug development value chain.

Advances in Expression System Technology. Cell-free protein expression systems now enable synthesis of complex molecules, including toxic proteins, membrane proteins, and post-translationally modified proteins that conventional cell-based systems cannot efficiently produce. Integration of computational biology and machine learning is further improving system design, while microfluidics and high-throughput genome editing are expanding the overall efficiency of protein production.

Growth of the CRO and CDMO Sector. Contract research and development organizations are scaling their protein expression capabilities to serve a biopharma industry that increasingly outsources early-stage manufacturing. This structural shift in how drug companies manage their supply chains creates durable, recurring revenue for service providers across the protein expression value chain.

IP Activity and Patent Momentum. More than 6,500 protein expression patents granted since 2023 indicate that companies are actively protecting new methods, host systems, and processing technologies. High patent volumes historically precede commercialization waves, and the current filing density points to a near-term expansion of commercially available expression solutions.

MARKET SEGMENTATION
By type of protein expression system, mammalian expression holds the largest market share and will remain dominant through 2035. The reason is structural: mammalian cells produce proteins with native architecture, high levels of post-translational modifications, and full functional activity. Approximately 85% of all biopharmaceuticals are manufactured using mammalian cell cultures, which anchors the segment's commercial primacy. The mammalian expression system market alone currently stands at approximately USD 1.3 billion.

By product offering, kits and reagents currently capture the largest revenue share, supported by their role in optimizing expression through solubility tags, purification tags, and protease cleavage sites. Protein expression services account for the offerings of more than 80% of market participants. The therapeutics application segment is growing at a faster CAGR than research and diagnostics, reflecting the shift from academic protein research toward clinical and commercial drug manufacturing. Among end-users, pharmaceutical and biotechnology companies hold the largest share, and in-house operations are growing faster than outsourced ones as companies prioritize intellectual property protection and supply chain control.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/protein-expression-market/request-quote.html

REGIONAL INSIGHTS
North America accounts for approximately 50% of the global protein expression market and will maintain that position through 2035. The US drives this dominance through expedited regulatory approval timelines, deep infrastructure for advanced biomanufacturing, and the concentration of major pharmaceutical and biotechnology companies investing in next-generation protein production. North America and Europe together capture roughly 75% of global market share, with Europe's growth supported by rising chronic disease prevalence across conditions including cancer and diabetes.

Asia-Pacific is the fastest-growing region, projected to advance at a CAGR of 10.0% through 2035, outpacing the global average by over two percentage points. Lower manufacturing costs, a large and skilled scientific workforce, and increasingly supportive regulatory environments in China, India, South Korea, and Japan are collectively drawing biopharma investment into the region. The January 2026 installation of Nuclera's eProtein Discovery systems at two Taiwanese universities signals that academic and early-stage commercial adoption in Asia-Pacific is already underway.
_
COMPETITIVE LANDSCAPE
The protein expression market features a fragmented field of both established global players and focused niche providers. Key companies include Agilent Technologies, Ajinomoto Bio-Pharma Services, Aldevron, Cayman Chemical, Charles River Laboratories, Domainex, Eurofins CALIXAR, GeNext Genomics, GenScript Biotech, Lonza, Merck KGaA, New England Biolabs, ProMab, Promega, ProteoGenix, QIAGEN, Sartorius, Synbio Technologies, Syngene, Takara Bio, Thermo Fisher Scientific, and WuXi Biologics.

The competitive dynamic is currently defined by portfolio breadth and service integration rather than price alone. Most participants offer prokaryotic expression systems as a baseline due to low cost and high yield, but the differentiation battleground is mammalian and cell-free systems, where technical complexity commands higher margins. Strategic collaborations, as seen with the Nuclera-Cytiva partnership, and proprietary platform launches like WuXi Biologics' EffiX, indicate that companies are competing on technological depth and speed-to-production rather than through consolidation alone. The market is not yet concentrating around a small number of dominant players; fragmentation persists, which continues to open space for specialized providers.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/protein-expression-market/106.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.